Printer Friendly

IDM Obtains a Patent in the USA That Protects Its Therapeutic Approach to Dendritic Cell Based Anti-Cancer Vaccines.

Business Editors/Health & Medical Writers

PARIS--(BUSINESS WIRE)--Sept. 5, 2002

Immuno-Designed Molecules, S.A. (IDM) today announces that it has been issued a patent in the United States, concerning blood monocyte-derived antigen presenting cells, which have the characteristics of mature dendritic cells.

This is the first patent in the US which specifically protects IDM's therapeutic approach based on dendritic cells.

These cells are known to be able to prime the immune response and secrete an environment of immunostimulating cytokines. These cells are used in the preparation of IDM's cellular vaccines, including Uvidem(TM) and Eladem(TM). Uvidem is currently in a Phase II trial for the treatment of melanoma and is being developed in collaboration with Sanofi-Synthelabo, while Eladem is in a Phase II trial for the treatment of prostate cancer.

This patent gives general coverage to IDM's dendritic cells meaning it covers their usage and the procedures used to obtain them. The patent is valid until 2019, and IDM is currently awaiting its additional issuance in Europe, Japan, Canada and Australia.

Jean-Loup Romet-Lemonne, President and CEO of IDM, stated, "This new patent strengthens IDM's portfolio which already includes 126 patents, 36 of which have been issued internationally."

IDM - The Immunogenics Company(R)

IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer.

For more information, please visit IDM's Web site,

http://www.idm-biotech.com

IDM Paris Headquarters

172 rue de Charonne

75011 Paris FRANCE

tel +33 (0) 1 40 09 04 11

fax +33 (0) 1 40 09 04 25

e-mail idm@idm-biotech.com
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 5, 2002
Words:325
Previous Article:Intel and Microsoft Collaborate With SAP to Announce Early Access to SAP Solutions On Intel Itanium 2-Based Systems.
Next Article:S&P: 'A+' Rating Assigned to QBE LYON.


Related Articles
Immune cells primed for cancer vaccine.
Immune attack on cancer: researchers spur the immune system to rout malignancies.
Fused cells hold promise of cancer vaccines.
GERON REGAINS RIGHTS FOR TELOMERASE INHIBITORS.
Immune cells target cancerous tissue. (Vaccine Power).
IDM Obtains Its First Japanese Patent.
PRIMA BIOMED SECURES KEY CANCER PATENT IN U.S.
IDM Obtains Its Second Patent in Japan.
Tiny bubbles: vesicles that cells spit out are implicated in cancer and AIDS.
Biotechnology and drug discovery: from bench to bedside.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters